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ABSTRACT 
Purpose: To evaluate the incidence and the associated factors of rectal toxicity in patients with 
prostate cancer undergoing permanent seed implantation (PI) with or without external beam 
radiation therapy (EBRT) in a nationwide prospective cohort study in Japan (J-POPS) during the 
first 2 years. 
Methods and Materials: 2,339 subjects were available for the analyses. Rectal toxicity was 
evaluated using the NCI-CTCAE version 3.0. 
Results: The 3-year cumulative incidence for Grade ≥2 rectal toxicity was 2.88%, 1.76% and 
6.53% in all subjects, PI group and EBRT combination therapy group, respectively. On multivariate 
analysis, among all subjects, Grade ≥2 rectal toxicity was associated with rectal volumes receiving 
100% of the prescribed dose (R100) (p <0.0001) and EBRT combination therapy (p = 0.0066). 
R100 in the PI group (p = 0.0254), and R100 (p = 0.0011) and interactive planning (p = 0.0267) in 
the EBRT combination therapy group were also associated with Grade ≥2 toxicity. The 3-year 
cumulative incidence of Grade ≥2 rectal toxicity was 3.80% and 1.37% for R100 ≥1 mL and R100 
<1 mL, respectively in the PI group (p = 0.0068), and 14.09% and 5.52% for R100 ≥1 mL and 
R100 <1 mL, respectively in the EBRT combination therapy group (p = 0.0070). 
Conclusions: Rectal toxicity was relatively rare in this study compared to previous reports. For 
Japanese prostate cancer patients, R100 <1 mL in both PI and EBRT combination therapy groups 
and interactive planning in EBRT combination therapy group may be effective in decreasing the 
incidence of rectal toxicity.  
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INTRODUCTION 
Permanent seed implantation (PI) has become a standard treatment option for patients with 
localized prostate cancer, with long-term local and biochemical control similar to outcomes 
observed after radical prostatectomy and external beam radiation therapy (EBRT) (1).  
  However, PI can lead to rectal toxicity, because the rectum, fixed in position and close to the 
prostate, often receives a large radiation dose with PI (2). Rectal toxicity is the third late effect of 
brachytherapy, after the urinary and sexual toxicity. Rectal toxicity of PI is variable in its 
presentation and can range in severity from mild, self-limited proctitis to more severe cases of 
ulceration and fistula formation (3–5).  
The number of patients with prostate cancer treated with PI has increased rapidly in Japan, and 
over 19,000 patients had been treated in 109 institutions at the end of 2011 (6). To evaluate the 
safety and efficacy of PI for prostate cancer, a nationwide prospective cohort study entitled the 
Japanese Prostate Cancer Outcome Study of Permanent Iodine-125 (I-125) Seed Implantation 
(J-POPS; NCT00534196) was initiated in July 2005 (7). A total of 2,354 subjects were enrolled 
in the study during the first 2 years.  
Ohashi et al. made the preliminary report evaluating the urinary and rectal toxicity in 2,339 
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subjects treated with PI enrolled in the J-POPS during the first 2 years (8). In this study, we 
describe rectal toxicity in more detail and evaluate factors associated with rectal toxicity in the 
same subjects. 
 
 
METHODS AND MATERIALS 
Although published previously (7, 8), a brief description of methods and materials are outlined 
below. 
 
Patient eligibility 
The J-POPS study is a large multi-institutional prospective cohort study to investigate the 
clinical effects of PI for localized prostate cancer in Japan (7). The enrollment of the subjects for 
this study has started in July 2005 and continued till December 2010. Finally 6,927 participants in 
46 institutes had been registered and been followed up still now. 
All subjects were histologically confirmed as having adenocarcinoma of the prostate and 
clinically diagnosed as having localized disease. There was no limitation for age, and all subjects 
gave written informed consent for enrollment in the J-POPS study. Inclusion and exclusion criteria 
of the participants followed the recommendations of the American Brachytherapy Society (9). 
A total of 2,354 participants were enrolled in this study during the first 2 years. Out of 2,354 
participants, background characteristics and baseline data were available in 2,339 patients. 
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Treatment design 
All participants were treated with loose I-125 seeds. Modified peripheral loading or modified 
uniform loading was generally recommended for seed placement. The clinical target volume (CTV) 
was defined as the prostate volume including an added treatment margin of 3–5 mm in all 
directions, except for less than 2 mm in the posterior direction.  
For PI alone as radiation therapy (PI group), a dose of 144 Gy was prescribed. According to the 
planning goals, V100 for the CTV (the percent volume of the CTV receiving 100% of the 
prescription dose) had to be over 90% or D90 for the CTV (the minimal dose received by 90% of 
the CTV) had to be 144–180 Gy. The maximum urethral dose had to be <200 Gy, whereas that for 
the rectum had to be <200 Gy in any slice.  
For EBRT combination therapy (EBRT combination therapy group), the prescription dose for PI 
was 100–110 Gy and that for EBRT was 40–50 Gy with 1.8–2.0 Gy/fraction. As for EBRT, the 
target volume consisted of the prostate gland, seminal vesicles, small pelvis, and/or whole pelvis. 
EBRT was performed either before PI or approximately 1 month after PI. The maximum urethral 
and rectal dose for PI had to be <150% of the prescription dose. All the treatment techniques, such 
as 2-dimensional radiation therapy, 3-dimensional conformal radiation therapy, and 
intensity-modulated radiation therapy were allowed in this protocol. 
Computed tomography (CT) images, taken at 1–3 mm slice width, were obtained approximately 
1 month after PI for postimplant dosimetric evaluation. Dose-volume histograms (DVH) for the 
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prostate, urethra, and rectum were computed to obtain post-planning distribution data. The 
calculated dosimetry parameters were the percent volumes of the prostate receiving 100% and 
150% of the prescribed dose (V100 and V150, respectively) and the values of the minimal dose 
received by 90% of the prostate volume (D90). The rectal dose was expressed as the rectal volume 
in cubic centimeters that received 100% and 150% of the prescribed dose (R100 and R150, 
respectively). The urethral dose was expressed as the values of the minimal dose received by 90% 
and 5% of the urethra volume (U-D90 and U-D5, respectively) and the urethral volume receiving 
200% of the prescribed dose (U200). 
  Patient information is shown in Tables 1 and 2. 
 
Toxicity scoring and follow-up protocol 
The scheduled follow-up assessments involved prostate-specific antigen (PSA) blood tests and 
physical examinations every 3 months for the first 2 years, and every 6 months thereafter for 5 
years. Toxicity was evaluated by physicians, mainly urologists, at 3, 12, 24, and 36 months after 
completion of radiation therapy.  
The rectal toxicity was graded according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI-CTCAE), version 3.0, for proctitis and rectal bleeding (10). In 
this system, Grade 1 toxicity included mild adverse events (rectal discomfort or rectal bleeding that 
did not require intervention). Grade 2 toxicity included moderate adverse events (proctitis or rectal 
bleeding requiring medical intervention or minor cauterization). Grade 3 toxicity included severe 
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adverse events (proctitis requiring operative intervention or rectal bleeding requiring transfusion, 
interventional radiology, or endoscopic or operative intervention). Grade 4 toxicity included 
life-threatening or disabling adverse events (rectal perforation or rectal bleeding requiring major 
urgent intervention). 
Acute toxicity was defined as symptoms occurring by 3 months after radiation therapy, and late 
toxicity was defined as symptoms occurring beyond 3 months after radiation therapy. 
 
Statistical analysis 
We estimated the cumulative incidence rate for Grade ≧2 rectal toxicity by the Kaplan Meier 
method to take into account of censored observations. We also identified the factors associated with 
Grade ≥2 rectal toxicity by the Cox proportional hazard model. Probability (p) values of <0.05 
were defined to be significant. Multivariate analysis was performed to analyze factors that were 
found to be significantly associated with Grade ≥2 rectal toxicity in the univariate analysis. 
  Statistical analyses were performed by SAS 9.1.3 statistical software (SAS Institute Inc., Cary, 
NC, USA). All statistical analyses were carried out at the Translational Research Informatics 
Center (TRI) in the Foundation for Biochemical Research and Innovation (FBRI), a public interest 
incorporated foundation. 
 
Ethical Considerations 
 The ethical review committee of the TRI (Approval no. 05-01; May 6, 2005) and all of the 
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institutional review boards of the participating facilities approved the study. 
 
 
RESULTS 
Incidence of acute and late rectal toxicity 
  The incidence of rectal toxicity was assessed at 3, 12, 24, and 36 months after completion of 
radiation therapy in 2,336, 2,310, 2,249, and 2,188 subjects, respectively. 
The frequency of acute, late, and total rectal toxicity are shown in Table 3.  
The 3-year cumulative incidence rate for Grade ≥2 rectal toxicity was 2.88% for all subjects, 
1.76% for the PI group, and 6.53% for the EBRT combination therapy group (Fig. 1a). The 3-year 
cumulative incidence rate for Grade ≥2 proctitis was 1.57% for all subjects, 1.07% for the PI group, 
and 3.18% for the EBRT combination therapy group. The 3-year cumulative incidence rate for 
Grade ≥2 rectal bleeding was 1.71% for all subjects, 0.75% for the PI group, and 4.84% for the 
EBRT combination therapy group. 
Only 3 subjects (0.55%; 3/547) in the EBRT combination therapy group experienced Grade 3 
toxicity. Out of these 3 subjects, 2 had their symptoms resolved with argon plasma coagulation or 
hyperbaric oxygen therapy. One patient developed intractable bleeding and a rectourethral fistula, 
and a diverting colostomy was performed. 
 
Factors associated with Grade ≥2 rectal toxicity 
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Tables 4, 5, and 6 show the results of the univariate and multivariate analyses using the Cox 
proportional hazard model for the effect of various factors on the incidence of Grade ≥2 rectal 
toxicity among all subjects, in the PI group, and in the EBRT combination therapy group, 
respectively. 
On multivariate analysis, among all subjects, Grade ≥2 rectal toxicity was associated with rectal 
volumes receiving 100% of the prescribed dose (R100) (hazard ratio [HR], 1.885; 95% confidence 
interval [CI], 1.383–2.569; p <0.0001) and EBRT combination therapy (HR, 2.815; 95% CI, 1.334–
5.939; p = 0.0066). R100 in the PI group (HR, 1.655; 95% CI, 1.064–2.574; p = 0.0254), and R100 
(HR, 1.977; 95% CI, 1.314–2.974; p = 0.0011) and interactive planning (HR, 0.472; 95% CI, 
0.243–0.917; p = 0.0267) in the EBRT combination therapy group was also associated with Grade 
≥2 toxicity. 
In the PI group, the 3-year cumulative incidence rate of Grade ≥2 rectal toxicity exceeded 3% 
with R100 ≥ 1 mL; 3.80% for R100 ≥ 1 mL, and 1.37% for R100 < 1 mL (HR, 2.757; 95% CI, 
1.282–5.929; p = 0.0068) (Fig. 1b). In the EBRT combination therapy group, the 3-year cumulative 
incidence rate of Grade ≥2 rectal toxicity exceeded 10% with R100 ≥ 1 mL; 14.09% for R100 ≥ 1 
mL, and 5.52% for R100 < 1 mL (HR, 2.744; 95% CI, 1.286–5.857; p = 0.0070) (Fig. 1c). In the 
EBRT combination therapy group, the 3-year cumulative incidence rate of Grade ≥2 rectal toxicity 
was 4.87% for interactive planning and 10.25% for other plannings (Fig. 1d). 
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DISCUSSION 
  Rectal toxicity is the third late effect of brachytherapy, after the urinary and sexual toxicity, and 
many publications have described the incidence and severity of rectal toxicity after PI (3, 5, 11–15). 
However, no reports have included more than 1,000 patients and been prospectively designed. To 
our knowledge, this is the largest prospective report of rectal toxicity after PI. 
Grade ≥2 rectal toxicity is reported to occur in 2.0–10.4% of patients treated with PI (5, 11–16) 
and in 8.0–18.0% of patients treated with EBRT combination therapy (11, 15–17). In our study, the 
3-year cumulative incidence rate of Grade ≥2 rectal toxicity was 1.76% for the PI group and 6.53% 
for the EBRT combination therapy group. These findings were relatively favorable results as 
compared to other studies. We assume that this is largely attributable to the rectal dose being lower 
than those in other studies. The mean and median R100 in all patients was 0.48 mL and 0.30 mL in 
our study, whereas other studies have reported a mean or median R100 of 0.79–1.49 mL (5, 11, 18, 
19). This might be explained by the superior quality of the technique used at these institutions. 
Training workshops have been held at regular intervals in Japan to maintain or improve the 
technical level of PI (6), and all the institutions in this study have participated the workshops. In 
each institution, PI treatment was performed with the strict aim of sparing the rectum. Additionally, 
a smaller prostate volume (PV) might result in a lower rectal dose. McNeely et al. (20) and Patil et 
al. (19) reported that the rectal dose increased in tandem with an enlarging PV. The mean and 
median PV in all subjects was 25.90 mL and 25.19 mL in our study, whereas the aforementioned 
studies have reported a mean or median PV of 28.0–38.5 mL (5, 11, 18, 19).  
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Factors reportedly associated with rectal toxicity in PI include the addition of EBRT (15, 17, 
21–24), rectal dose (3, 11, 13–15, 25), prostate dose (15, 26, 27), advanced age (22, 21), 
inflammatory bowel disease (22), and smoking status (21). Prostate volume (19, 20) and body mass 
index (19) were reported to be associated with the rectal dose in PI. Diabetes mellitus, prior 
abdominal surgery, and androgen deprivation therapy were reported to be associated with rectal 
toxicity in EBRT (28). We performed this study on the basis of the hypothesis that these factors 
might be associated with rectal toxicity. Indeed, when we analyzed all 2,339 cases, Grade ≥2 rectal 
toxicity was associated with R100 and the addition of EBRT. R100 in the PI group and R100 and 
interactive planning in the EBRT combination therapy group were also associated with Grade ≥2 
rectal toxicity. With regard to the planning process, several investigators have reported that DVH 
parameters are significantly better with intraoperative planning than preplanning (29). Zelefsky et 
al. (30) reported a more rapid resolution of Grade 2 urinary-related symptoms with interactive 
planning than preplanning. However, prior to our study, no reports have demonstrated that rectal 
toxicity was rarer with intraoperative planning than preplanning. 
In this study, the 3-year cumulative incidence rate of Grade ≥2 rectal toxicity was 3.80% for 
R100 ≥1 mL and 1.37% for R100 <1 mL, respectively, in the PI group (HR, 2.757; 95% CI, 1.282–
5.929; p = 0.009), and 14.09% for R100 ≥1 mL and 5.52% for R100 <1 mL, respectively, in the 
EBRT combination therapy group (HR, 2.744; 95% CI, 1.286–5.857; p = 0.009). Snyder et al. (13) 
have shown that Grade ≥2 proctitis at 5 years was seen in 18% of patients with R100 >1.3 mL and 
in 5% of patients with R100 ≤1.3 mL among patients receiving PI (p = 0.001). Keyes et al. (5) have 
                                                                    
 
11 
11 
shown that, for PI, late Grade ≥2 rectal toxicity was seen in 10.6% of patients with R100 ≥1 mL 
and in 6.7% of patients with R100 ≤1 mL. Shiraishi et al. (31) have shown that, for EBRT 
combination therapy, Grade 2 rectal bleeding was seen in 22.0% of patients with R100 >1 mL and 
in 8.1% of patients with R100 ≤1 mL. Keyes et al. (5), Tran et al. (32), and Han et al. (33) 
suggested keeping R100 <1 mL. These reports are consistent with our data in terms of association 
of R100 with rectal toxicity. 
This study has some limitations. First, interobserver variability in postimplant dosimetry 
exists because this study was a multicenter study. Contouring the prostate and rectum on 
postimplant CT images can be challenging (34). However, because the above-mentioned training 
workshops in which all the institutions in this study have participated include the technical 
instruction of postimplant dosimetry, interobserver variability in this study should be minimized. 
Secondly, we did not analyze the rectal DVH parameters for EBRT in the EBRT combination 
therapy group, although Shiraishi et al. (31) reported that rectal V30 (the percent volumes 
receiving doses higher than 30 Gy) for EBRT was associated with Grade 2 rectal bleeding in 
patients receiving EBRT combination therapy and rectal DVH parameters were reported to be 
associated with rectal toxicity in patients receiving EBRT (28). Finally, the follow-up period may 
be too short to observe late rectal toxicity. The final follow-up of toxicity was at 36 months in our 
protocol, although rectal toxicity could appear after more than 3 years. 
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CONCLUSIONS 
Rectal toxicity after PI with and without EBRT was relatively rare in our study as compared to 
previous reports. For Japanese patients with prostate cancer treated with PI, R100 <1 mL both in PI 
and EBRT combination therapy and interactive planning in EBRT combination therapy may be 
effective in decreasing the incidence of rectal toxicity.  
 
 
FIGURE CAPTIONS 
Fig. 1. (a) Cumulative Grade ≥2 rectal toxicity rates for the PI group and the EBRT combination 
therapy group. (b) Cumulative Grade ≥2 rectal toxicity rates for R100 ≥ 1 mL and R100 < 1 mL in 
the PI group. (c) Cumulative Grade ≥2 rectal toxicity rates for R100 ≥ 1 mL and R100 < 1 mL in 
the EBRT combination therapy group. (d) Cumulative Grade ≥2 rectal toxicity rates for interactive 
planning and other plannings in the EBRT combination therapy group. 
PI = permanent seed implantation; EBRT = external beam radiation therapy; R100 = the rectal 
volume in cubic centimeters that receiving 100% of the prescribed dose. 
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Table 1  Descriptive statistics of patient information  
Factors n mean SD minimum median maximum missing 
Age (year) 2339 68.07 6.37 45 69.0 89 0 
   PI group 1792 67.81 6.47 45 68.5 89 0 
   EBRT combination group 547 68.92 5.98 52 70.0 88 0 
BMI (kg/m2) 2268 23.60 2.67 14.69 23.51 35.70 71 
   PI group 1721 23.63 2.62 14.69 23.57 32.78 71 
   EBRT combination group 547 23.50 2.83 15.50 23.38 35.70 0 
PSA (ng/ml) * 2321 7.98 4.10 1.60 6.80 42.00 18 
   PI group 1775 7.19 3.11 1.60 6.47 41.80 17 
   EBRT combination group 546 10.57 5.60 1.92 9.33 42.00 1 
Prostate volume (ml) † 2339 25.90 8.23 7.00 25.19 71.00 0 
   PI group 1792 26.40 8.17 7.30 25.75 71.00 0 
   EBRT combination group 547 24.25 8.22 7.00 23.53 61.90 0 
Implanted seed number 2339 68.26 16.55 25 69.0 120 0 
   PI group 1792 73.26 14.74 26 73.0 120 0 
   EBRT combination group 547 51.87 10.42 25 50.0 85 0 
Activity/seed (MBq) 2339 13.39 1.01 9.79 13.10 15.30 0 
   PI group 1792 13.38 0.95 9.79 13.10 15.30 0 
   EBRT combination group 547 13.41 1.20 10.62 13.10 15.30 0 
Total activity (MBq) 2339 912.13 225.09 332.50 917.00 1572.00 0 
   PI group 1792 978.44 201.50 340.60 969.40 1572.00 0 
   EBRT combination group 547 694.91 148.55 332.50 679.32 1224.00 0 
Prostate V100 (%) 2327 93.89 5.23 56.30 95.13 100.00 12 
   PI group 1781 93.66 5.19 56.30 94.80 100.00 11 
   EBRT combination group 546 94.62 5.30 56.47 96.07 99.97 1 
Prostate V150 (%) 2327 62.38 13.51 16.32 63.32 98.10 12 
   PI group 1781 62.16 13.45 18.42 62.94 94.60 11 
   EBRT combination group 546 63.08 13.69 16.32 64.21 98.10 1 
Prostate D90 (Gy) 2327 151.20 27.40 57.80 152.36 231.90 12 
  PI group 1781 160.87 22.71 57.80 160.60 231.90 11 
   EBRT combination group 546 119.67 14.78 60.22 120.40 191.60 1 
R100 (ml) 2231 0.48 0.58 0.00 0.30 4.78 108 
   PI group 1685 0.50 0.59 0.00 0.30 4.78 107 
   EBRT combination group 546 0.43 0.53 0.00 0.26 3.73 1 
R150 (ml) 2231 0.05 0.13 0.00 0.00 1.51 108 
   PI group 1685 0.05 0.13 0.00 0.00 1.51 107 
   EBRT combination group 546 0.04 0.11 0.00 0.00 1.21 1 
Urethral D90 (Gy) 2230 133.24 32.71 7.90 131.55 336.54 109 
   PI group 1684 140.70 32.53 7.90 140.43 336.54 108 
   EBRT combination group 546 110.24 20.16 40.00 110.68 184.73 1 
Urethral D5 (Gy) 1996 212.08 46.96 97.60 210.00 426.99 343 
   PI group 1479 227.26 41.03 119.00 223.39 426.99 313 
   EBRT combination group 517 168.66 34.01 97.60 161.99 338.36 30 
U200 (ml) 2230 0.06 1.97 0.00 0.00 92.90 109 
   PI group 1684 0.07 2.27 0.00 0.00 92.90 108 
   EBRT combination group 546 0.01 0.05 0.00 0.00 0.60 1 
SD = standard deviation; PI = permanent seed implantation; EBRT = external beam radiation therapy; BMI = body 
mass index; PSA = prostate-specific antigen; VXX = the percent volumes receiving XX% of the prescribed dose; 
DXX = the values of the minimal dose received by XX% of the volume; RXX = the rectal volume in cubic 
centimeters that receiving XX% of the prescribed dose; U200 = the urethral volume receiving 200% of the 
prescribed dose 
*PSA was measured before the latest biopsy. 
†Prostate volume was measured pre-implantation. 
 
 Table 2  Baseline characteristics of patients 
Factors 
PI group 
 EBRT combination 
group 
Total 
n % n % n % 
Diabetes       
   Yes 113 6.31  44 8.04  157 6.72  
   No 1678 93.69  503 91.96  2181 93.28  
Rectal cancer       
   Yes 12 0.67  5 0.91  17 0.73  
   No 1779 99.33  542 99.09  2321 99.27 
Bladder cancer       
   Yes 10 0.56  6 1.10  16 0.68  
   No 1781 99.44  541 98.90  2322 99.32  
Smoking status       
   Yes 239 14.60  74 13.83  313 14.41  
   No 1398 85.40  461 86.17  1859 85.59  
Drinking status       
   Yes 1111 68.03  394 73.78  1505 69.45  
   No 522 31.97  140 26.22  662 30.55  
Gleason score       
   8 or more 12 0.67  72 13.16  84 3.60  
   7 545 30.46  384 70.20  929 39.77  
   6 or less 1232 68.87  91 16.64  1323 56.64  
Clinical stage: T Stage       
   T3 2 0.11  16 2.93  18 0.77  
   T2 394 22.02  207 37.84  601 25.73  
   T1 1388 77.59  324 59.23  1712 73.29  
   TX 5 0.28 - - 5 0.21 
Clinical stage: N Stage       
   N0 1776 99.27  546 99.82  2322 99.40  
   NX 13 0.73  1 0.18  14 0.60  
Clinical stage: M Stage       
   M0 1774 99.16  546 99.82  2320 99.32  
   MX 15 0.84  1 0.18  16 0.68  
Androgen deprivation therapy       
   Yes 764 42.63  390 71.30  1154 49.34  
   No 1028 57.37  157 28.70  1185 50.66  
Planning process       
   Interactive 772 43.08  374 68.37  1146 49.00  
   Others 1020 56.92  173 31.63  1193 51.00  
 Table 3  Crude frequency of rectal toxicities 
 
PI group    EBRT combination group All patients 
Acute Late Total Acute Late Total Acute Late Total 
n % n % n % n % n % n % n % n % n % 
Grade4 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 0 0.00 
Grade3 0 0.00 0 0.00 0 0.00 0 0.00 3 0.56 3 0.55 0 0.00 3 0.13 3 0.13 
Grade2 15 0.84 16 0.90 31 1.73 9 1.65 24 4.45 32 5.85 24 1.03 40 1.72 63 2.69 
Grade1 117 6.54 132 7.45 209 11.67 50 9.16 109 20.22 125 22.85 167 7.15 241 10.42 334 14.29 
Grade0 1658 92.63 1625 91.65 1551 86.60 487 89.19 403 74.77 387 70.75 2145 91.82 2028 87.72 1938 82.89 
Total 1790 100.00 1773 100.00 1791* 100.00 546 100.00 539 100.00 547 100.00 2336 100.0 2312 100.00 2338* 100.00 
PI = permanent seed implantation; EBRT = external beam radiation therapy. 
* One patient was missing due to loss to follow up. 
Table 4  Univariate and multivariate analyses for Grade ≥2 rectal toxicity among all patients 
Factors 
Univariate analysis Multivariate analysis 
n HR 95% CI p n HR 95% CI p 
Age (years) 2339 1.019 0.980–1.059 0.3501 
    BMI (kg/m2) 2268 0.956 0.871–1.049 0.3414 
    Prostate volume (ml) 2339 0.981 0.951–1.012 0.2226 
    Activity/seed (MBq) 2339 0.999 0.786–1.268 0.9920 
    Prostate V100 (%) 2327 0.972 0.934–1.012  0.1638 
    Prostate V150 (%) 2327 1.016 0.997–1.035 0.1014 
    Prostate D90 (Gy) 2327 0.983 0.974–0.991 0.0001* 2226 0.992 0.979–1.006 0.2637 
R100 (ml) 2231 1.701 1.259–2.297 0.0005* 2226 1.885 1.383–2.569 <.0001* 
R150 (ml)† 2231 7.418 2.862–19.223 <.0001* 
    Diabetes Yes 157 1.396 0.603–3.232 0.4355 
    No 2181 
       Rectal cancer Yes 17 2.186 0.303–15.753 0.4377 
    No 2321 
       Smoking status Yes 313 1.355 0.724–2.535 0.3421 
    No 1859 
       Drinking status Yes 1505 1.065 0.624–1.817 0.8176 
    No 662 
       Clinical stage T1 1712 
   
1637 
   T2 601 1.684 1.018–2.787 0.0425 571 1.360 0.811–2.282 0.2439 
T3 18 – – 0.9839 18 0.000 0.000 0.9854 
Androgen deprivation therapy Yes 1154 1.283 0.762–2.009 0.3886 
    No 1185 
       EBRT Yes 547 3.766 2.322–6.107 <.0001* 546 2.815 1.334–5.939 0.0066* 
No 1792 
   
1680 
   Planning process 
 
Interactive 1146 1.160 0.715–1.881 0.5470 
    Other 1193           
HR = hazard ratio; CI = confidence interval; Other abbreviations as in Table 1. 
*: Significant risk factor 
†: R150 is the collinearity factor of R100; therefore, R150 is excluded in the multivariate analysis. 
One patient was treated but lacked the data for the rectal toxicity; as a censored sample the patient was included for the 
calculation of HR. Therefore, total n=2339 if explanatory variables were measured for all the patients. 
 
 
  
Table 5  Univariate and multivariate analyses for Grade ≥2 rectal toxicity in the PI monotherapy group 
Factors 
Univariate analysis Multivariate analysis 
n HR 95% CI p n HR 95% CI p 
Age (years) 1792 0.991 0.939–1.046 0.7443 
    BMI (kg/m2) 1721 0.971 0.846–1.114 0.6715 
    Prostate volume (ml) 1792 0.964 0.919–1.010 0.1205 
    Activity/seed (MBq) 1792 1.077 0.751–1.546 0.6860 
    Prostate V100 (%) 1781 0.953 0.903–1.006 0.0805 
    Prostate V150 (%) 1781 1.008 0.982–1.036 0.5441 
    Prostate D90 (Gy) 1781 0.997 0.981–1.012 0.6798 
    R100 (ml) 1685 1.655 1.064–2.574 0.0254* 1685 1.655 1.064–2.574 0.0254* 
R150 (ml)† 1685 5.459 1.167–25.539 0.0311* 
    Diabetes Yes 113 2.224 0.778–6.355 0.1356 
    No 1678 
       Rectal cancer Yes 12 – – 0.9894 
    No 1779 
       Smoking status Yes 239 1.795 0.770–4.183 0.1754 
    No 1398 
       Drinking status Yes 1111 1.096 0.502–2.393 0.8184 
    No 522 
       Clinical stage T1 1388 
       T2 394 1.522 0.697–3.323 0.2917 
    T3 2 – – 0.9902 
    Androgen deprivation therapy Yes 764 1.109 0.547–2.249 0.7747 
    No 1028 
       Planning process Interactive 772 1.590 0.784–3.225 0.1990 
    Other 1020           
Abbreviations as in Table 4. 
*: Significant risk factor 
†: R150 is the collinearity factor of R100; therefore, R150 is excluded in the multivariate analysis. 
One patient was treated but lacked the data for the rectal toxicity; as a censored sample the patient was included for the 
calculation of HR. Therefore, total n=1792 if explanatory variables were measured for all the patients. 
 Table 6  Univariate and multivariate analyses for Grade ≥2 rectal toxicity in the EBRT combination therapy group 
Factors 
Univariate analysis Multivariate analysis 
n HR 95% CI p n HR 95% CI p 
Age (years) 547 1.032 0.976–1.092 0.2621 
    BMI (kg/m2) 547 0.956 0.846–1.081 0.4726 
    Prostate volume (ml) 547 1.014 0.975–1.054 0.4867 
    Activity/seed (MBq) 547 0.943 0.712–1.250 0.6847 
    Prostate V100 (%) 546 0.977 0.926–1.030 0.3872 
    Prostate V150 (%) 546 1.019 0.994–1.046 0.1423 
    Prostate D90 (Gy) 546 1.003 0.981–1.026 0.8029 
    R100 (ml) 546 2.026 1.332–3.082 0.0010* 546 1.977 1.314–2.974 0.0011* 
R150 (ml)† 546 14.320 4.247–48.288 <.0001* 
    Diabetes Yes 44 0.678 0.163–2.824 0.5932 
    No 503 
       Rectal cancer Yes 5 3.177 0.435–23.212 0.2546 
    No 542 
       Smoking status Yes 74 1.038 0.403–2.676 0.9377 
    No 461 
       Drinking status Yes 394 0.885 0.425–1.844 0.7450 
    No 140 
       Clinical stage T1 324 
       T2 207 1.176 0.602–2.297 0.6351 
    T3 16 – – 0.9899 
    Androgen deprivation therapy Yes 390 0.682 0.344–1.354 0.2864 
    No 157 
       Planning process Interactive 374 0.469 0.242–0.911 0.0254* 374 0.472 0.243–0.917 0.0267* 
Other 173 
   
172 
   Abbreviations as in Table 4. 
*: Significant risk factor 
†: R150 is the collinearity factor of R100; therefore, R150 is excluded in the multivariate analysis. 
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